List of Vaccines Companies in Denmark - 11

AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.

From our headquarters in Copenhagen, we develop and manufacture vaccines, diagnostics, and therapeutic solutions for the world. We are proud to contribute to disease control in more than 50 countries through our collaboration with WHO and UNICEF. We have more than 600 colleagues, and we pride ourselves on being a diverse workforce with passports from 39 nationalities. Being part of AJ Vaccines means joining a common mission towards a healthier and safer world. Whether you're an experienced professional or an emerging talent, you'll find a platform here to contribute, innovate, and create meaningful change.

We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. Our values – our Bavarian Nordic DNA, as we call it – is what guides our actions. We act as persistent pioneers, we are embracing change, we value being boosted by the team, and we believe in protecting lives every day. If that is also a part of your DNA, we invite you to join us in Bavarian Nordic! We are a global team of more than 1,400 dedicated people with diverse backgrounds and viewpoints who are bound together by our commitment to protect lives every day. We believe in creating an inclusive and flexible workplace with a strong focus on personal and professional development, because we need each other to take things further. We operate in a world in constant flux and always explore new opportunities. So, if you are open-minded and have the willpower to succeed, we might just be a perfect fit.

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.

ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase III-stage COVID-19 vaccine, ABNCoV2, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The cVLP and ExpreS2 TM platforms are also basis for a proprietary HER2-cVLP breast cancer vaccine, ES2B-C001, which has proven preclinical proof of concept and is on path towards clinical investigations. The development pipeline also has projects based on the ExpreS2 platform alone, including multiple clinical-stage malaria vaccine projects sponsored by academic partners, as well as novel preclinical-stage influenza and CMV vaccines, the latter in a research collaboration with Evaxion Biotech. Since founded in 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in its 34%-owned associated company AdaptVac that was founded in 2017. ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq First North Growth Market, Stockholm (Ticker: EXPRS2).

GlyProVac has via its proprietary platform technology, BEMAP, discovered that 1) O-linked protein glycosylation is a surprisingly abundant post translational modification in bacterial, 2) glycoproteins are linked to increased immunogenicity. GlyProVac aim to be the first to explore and exploit this novel class of antigens as candidates for vaccine development. The GlyProVac lead YghJ/SslE/AcfD is a conserved protein with a known biological function and has vaccine potential not only in ETEC but also in UPEC. Using BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. We are in the PoC phase and currently work to establish that glycosylated YghJ elicit a more protective immune response compared to the non-glycosylated version.

Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases

Immudex is a pioneering life science company spearheading the global adoption of precision immune monitoring. Since 2009, Immudex has been striving to provide researchers worldwide with reliable tools to monitor the cellular immune response accurately. Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. To that end, Immudex markets prime Dextramer® and dCODE® (DNA-barcoded) MHC multimer technologies that grant researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells. Additionally, Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies. Research, development, and commercial activities are headquartered in Copenhagen, Denmark, with operations in North America out of Fairfax, Virginia. Find out more at www.immudex.com.

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.

Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.